Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | KIT | P10721 | 10/20 | 0.60 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.59 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708998 | 0.89 | ABL1 (0.55) | ABL1KITMAP3K11AAK1MAP4K1 | |
| SCHEMBL12762980 | 0.87 | ABL1 (0.69) | ABL1KITAAK1MAP4K1PIK3CA | |
| SCHEMBL12762937 | 0.86 | ABL1 (0.71) | ABL1KITMAP3K11AAK1MAP4K1 | |
| SCHEMBL20812402 | 0.86 | KIT (0.72) | ABL1KITAAK1MAP4K1PIK3CA | |
| SCHEMBL8321166 | 0.86 | KIT (0.73) | ABL1KITMAP3K11AAK1MAP4K1 | |
| SCHEMBL12763228 | 0.85 | ABL1 (0.65) | ABL1KITMAP3K11AAK1MAP4K1 | |
| SCHEMBL12763560 | 0.85 | KIT (0.74) | ABL1KITAAK1MAP4K1PIK3CA | |
| SCHEMBL12762873 | 0.85 | KIT (0.61) | ABL1KITMAP3K11AAK1MAP4K1 | |
| SCHEMBL14043043 | 0.84 | ABL1 (0.80) | ABL1KITMAP3K11AAK1MAP4K1 | |
| SCHEMBL12762948 | 0.83 | ABL1 (0.58) | ABL1KITMAP3K11AAK1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | MAP4K2, PDXK, MAP4K1 | ABL1 348/4885KIT 1085/4885MAP3K11 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.